SEC-sourced researchBeta
SABS
SAB Biotherapeutics, Inc.
Company comparison ↗
Data passport
- CIK
- 0001833214
- Exchange
- Nasdaq
- Business activity
- — · SIC 2836
- Financial inputs
- 6/6
- Filing date
- Sep 18, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2024 | 1,322,410.0000 | Mar 9, 2026 |
| December 2025 | 0.0000 | Mar 9, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 0.0000 | 13,273,683.0000 | -44,775,111.0000 | 172,809,969.0000 | 21,315,594.0000 | Mar 9, 2026 |
| December 2024 | 1,322,410.0000 | -34,105,309.0000 | -34,292,009.0000 | 44,195,469.0000 | 18,225,893.0000 | Mar 9, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $0 | December 2025 | Mar 9, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $1.32M | December 2024 | Mar 9, 2026 | 10-K |
| Net incomeNetIncomeLoss | $13.27M | December 2025 | Mar 9, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$44.78M | December 2025 | Mar 9, 2026 | 10-K |
| Total assetsAssets | $172.81M | December 2025 | Mar 9, 2026 | 10-K |
| Total liabilitiesLiabilities | $21.32M | December 2025 | Mar 9, 2026 | 10-K |